LSM3P2

Across TCGA pan-cancer cohorts, LSM3P2 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated LSM3P2 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LSM3P2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LSM3P2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

LIHC, ACC, and KICH are the cancer types where LSM3P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	III,IV	0.135	0.381	.001	84	view →
ACC	DFS	Tertile	III,IV	0.010	0.364	<.001	45	view →
KICH	DFS	Tertile	III,IV	0.025	0.773	<.001	36	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
SKCM	DFS	Tertile	III,IV	0.371	0.224	.013	33	view →
TGCT	DFS	Tertile	II,III,IV	0.368	0.953	.001	30	view →
UCEC	OS	Tertile	IV	0.758	0.351	.038	24	view →
THCA	OS	Quartile	IV	0.791	1.000	.002	19	view →
KIRC	DFS	Tertile	IV	0.208	0.503	.028	18	view →
PAAD	OS	Tertile	II,III,IV	0.377	0.596	.001	18	view →
LUAD	DFS	Tertile	IV	0.350	0.758	.005	18	view →
KIRP	DFS	Tertile	III,IV	0.040	0.691	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

LSM3P2–LIHC (DFS)

Open the LIHC breakdown →